secwatch / observer
8-K filed June 4, 2025, 7:59 PM ET ticker LIMN CIK 0001971387
regulatory confidence high sentiment neutral materiality 0.45

Liminatus Pharma, Inc. (LIMN): Nasdaq/NYSE listing notice — Liminatus Pharma receives and resolves Nasdaq non-compliance for late 10-Q filing

Liminatus Pharma, Inc.

item 3.01item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Liminatus Pharma, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange
nasdaq
Notice
noncompliance notice
Deficiency
late filing
Rules
5250(c)(1)
Exact text from the filing
May 29, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Form 10-Q”). On June 2, 2025, the Company filed the Form 10-Q with the U.S. Securities and Exchange Commission. On June 3, 2025, the Company received a letter from the Staff stating that the Company had regained compli
View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-25-056421
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.